Comparing the current results to its competitors, Emmaus Life Sciences Inc reported Revenue increase in the 4 quarter 2025 by 24.62 % year on year, while most of its competitors have experienced contraction in revenues by -6.85 %, achieved in the same quarter.
Emmaus Life Sciences Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is highly competitive and subject to rapid technological change. It faces competition from large and small pharmaceutical and biotechnology companies, academic institutions, governmental agencies such as the National Institutes of Health, and public and private research institutions. Many competitors possess greater financial resources and expertise in areas including research and development, manufacturing, clinical trials, regulatory approvals, marketing, and sales. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. The success of the company’s product candidates, including Endari®, depends on factors such as safety, efficacy, convenience, pricing, proprietary and generic competition, and coverage and reimbursement availability. The company’s commercial prospects could be adversely affected if competitors develop products that are safer, more effective, or more convenient.
Morphic Holding Inc's business model revolves around the development and commercialization of novel integrin therapeutics. They utilize a platform that combines structural biology, medicinal chemistry, and computational biology to design and develop small-molecule drugs. By strategically targeting and inhibiting integrin receptors, Morphic aims to address various diseases while offering potential benefits to patients.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Kamada Ltd is a biopharmaceutical company that operates on a business model centered around developing and commercializing specialty plasma-derived therapeutics. The company focuses on leveraging its expertise in proprietary protein purification technology and plasma collection to produce and deliver high-quality therapeutic products. Kamada aims to address unmet medical needs in various therapeutic areas, providing innovative treatment options to patients worldwide.
Sources:
Emmaus Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Emmaus Life Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
